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ABSTRACT
Background and Objectives: Nitric oxide (NO) is a major endothelium dependent vasomediator and growth inhibitor. NO 
synthesis is catalyzed by endothelial nitric oxide synthase (eNOS), and NO can also produce peroxynitrite, which activates 
matrix metalloproteinases (MMPs). The purpose of this study was to determine the gene expression of eNOS and MMP-2 
in the lungs of a rat model of pulmonary hypertension after bosentan treatment. Materials and Methods: Six-week-old male 
Sprague-Dawley rats were treated as follows: control group, subcutaneous (sc) injection of saline; monocrotaline (MCT) 
group, sc injection of MCT (60 mg/kg); and bosentan group, sc injection of MCT (60 mg/kg) plus 20 mg/day bosentan oral-
ly. The rats were sacrificed after 1, 5, 7, 14 and 28 days. Results: The right ventricle/(left ventricle+septum) ratio significantly 
increased in the MCT group compared to the control group on day 14 and 28. The expression of eNOS messenger ribonucleic 
acid was significantly increased in the MCT group compared to the control group on day 28. MMP-2 gene expression was sig-
nificantly increased in the MCT-treated rats compared to the control group on day 5 and 28. Following bosentan treatment to 
reduce pulmonary hypertension, the expression levels of MMP-2 gene were significantly decreased on day 7 and 28. eNOS and 
tissue inhibitor of MMPs genes were also significantly decreased on day 28 after bosentan treatment. Conclusion: These re-
sults suggest that elevated eNOS expression may be responsible for MMP-2 activation. The causal relationship between eNOS 
and MMP-2 and their role in pulmonary hypertension require further investigations. (Korean Circ J 2011;41:83-90)
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Introduction
 
Pulmonary hypertension is a condition characterized by 
progressive increase in pulmonary vascular resistance, lead-
ing to right ventricular (RV) failure and death. To date, vari-
ous mechanisms underlying the development of pulmonary 
hypertension have been explored. One of which is the role of 
vasoactive mediators produced from the pulmonary vascular 
endothelium which regulates normal pulmonary vascular tone. 
Both nitric oxide (NO) and endothelin (ET)-1 have been id-
entified as major endothelium dependent vasomediator. NO 
is a potent, endogenous vasodilator which contributes not 
only to the local regulation of vascular smooth muscle tone, 
but also to smooth muscle cell (SMC) proliferation.
1) NO is pro-
duced in pulmonary endothelial cells (ECs) from the amino 
acid L-arginine, and molecular oxygen by endothelial nitric 
oxide synthase (eNOS).
2) This led to a hypothesis that eNOS 
expression might play a key role in the regulation of vascular 
tone. A number of clinical and animal experiments have in-
vestigated to test this hypothesis but have shown conflicting 
results. Whether the expression of eNOS is altered in associ-
ation with right ventricular hypertrophy (RVH) has not yet 
been fully elucidated. 
Bosentan is an orally active ET receptor antagonist which 
has a non-selective, dual action against ETA and ETB. It has been 
shown that bosentan significantly reduces pulmonary hyper-
tension, pulmonary vascular hypertrophy and RVH in rats with 84   Nitric Oxide Synthase and MMP-2 in Pulmonary Hypertension 
hypoxia-induced pulmonary hypertension.
3) Similarly, the 
development of pulmonary hypertension was attenuated by 
bosentan in rats treated with monocrotaline (MCT).
4) In this 
study, we used MCT to induce pulmonary hypertension and 
selective RVH in rats. Matrix metalloproteinases (MMPs) 
are a large family of endopeptidases which has an important 
role in the degradation of extracellular matrix (ECM). Previ-
ous studies have shown increased levels and activation of 
MMP-2 in pulmonary arteries from experimental pulmo-
nary arterial hypertension models, suggesting that MMPs 
contribute to the progression of pulmonary arterial hyper-
tension in animals.
5)6) The purposes of this study were to in-
vestigate the gene expressions of eNOS, MMP and tissue in-
hibitor of matrix metalloproteinases (TIMP) in the lungs of 
MCT induced pulmonary hypertension rats, and the effect 
of bosentan treatment on their gene expressions.
Materials and Methods
 
Six-week-old male Sprague-Dawley rats, weighing between 
200-250 g, were used for this study. All rats were house in cli-
mate-controlled conditions with a 12 hours light: 12 hours dark 
cycle, and had free access to chow and water. 
Pulmonary hypertension was induced by subcutaneous (sc) 
injection of 60 mg/kg MCT (Sigma Chemicals, St. Louis, 
MO, USA) dissolved in 0.5 N NaCl solution. The rats were 
grouped as follows: control (n=36), sc injection of normal sa-
line (0.1 mL/kg); MCT (n=36), sc injection of MCT; bosen-
tan (n=36), sc injection of MCT plus 20 mg/day bosentan (Ac-
telion Pharmaceuticals Ltd., Allischwil, Switzerland) by ga-
vage feeding. The rats were sacrificed after 1, 5, 7, 14 and 28 
days. Lung tissues were removed and immediately frozen at 
-70°C for enzyme analysis, post-fixed in 10% formalin, and 
processed routinely for paraffin embedding. The study proto-
cols were approved by the Institutional Review Board of the 
School of Medicine of Ewha Womans University.
Organ weights
The rats were weighed and observed for general appear-
ance during the study period. The animals were sacrificed at 
the scheduled time, and the hearts and lungs were rapidly 
removed. The wet weights of the RV, left ventricle and sep-
tum (LV+S), and lungs were measured, and the ratio of organ 
weight to body weight was calculated. The RV to LV+S ratio 
{RV/(LV+S)} was used as an index of RVH. 
Hemodynamic parameters 
The animals were placed in the supine position and instru-
mented with an arterial pressure line (Physiological Pressure 
Transducer, MLT1199; AD Instruments, Oxfordshire, UK). He-
modynamic parameters were recorded at baseline, and after 
5, 7, 14 and 28 days. The catheter was placed in the RV to esti-
mate the mean ventricular pressure. The mean right ventric-
ular pressure was measured. Arterial pressures were calibrat-
ed using input from an ambient-pressure reference (APR-1; 
Data Sciences). 
Matrix metalloproteinase-2 and nitric oxide level
in serum
At the scheduled times, serum was collected to determine 
MMP-2 and NO concentrations. Serum MMP-2 level was meas-
ured using a mouse immunoassay kit (Quantikine, Mouse 
MMP-2 Immunoassay kit, R&D system Inc., Minneapolis, MN, 
USA), and serum NO level was measured using molecular 
devices (Molecular Devices V-MAX 220 VAC enzyme link-
ed immuno sorbent assay reader, USA) by a sandwich en-
zyme immunoassay technique. A monoclonal antibody speci-
fic for MMP-2 had been pre-coated onto a microplate. Stan-
dards and samples were pipetted into the wells and any MMP 
present were bound by an immobilized antibody. After wash-
ing away any unbound substances, an enzyme-linked mono-
clonal antibody specific for MMP-2 was added to the wells. 
Following a wash to remove any unbound antibody-enzyme 
reagent, an enhanced luminal/peroxide substrate solution 
was added to the wells and light was produced in proportion 
to the amount of MMP-2 bound in the initial step. The iden-
tical method was used to measure NO. A microplate lumino-
meter was used to measure the intensity of the light emitted.
Lung microarray
Total RNA was extracted from the rat lung tissue using the 
TRI REAGENT (MRC, OH) according to the manufacturer’s 
instructions. Each total RNA sample (10 ug) was labeled with 
Cyanine (Cy5) conjugated dCTP (Amersharm, Piscataway, 
NJ) by a reverse transcription reaction using reverse transcrip-
tase, SuperScrip ll (Invitrogen, Carlsbad, California). The la-
beled cDNA was then concentrated using the ethanol precip-
itation method. Concentrated Cy5 labeled cDNAs were re-
suspended in 10 μL of hybridization solution (GenoCheck, 
Korea). After the labeled cDNAs were placed on Roche Nim-
bleGen Rat genome 12-plex array (Roche NimbleGen, Inc., 
WI) and covered by a NimbleGen H12 mixer (Roche Nim-
bleGen, Inc., WI). The slides were hybridized for 12 hours at 
42°C MAUI system (Biomicro systems, Inc. UT). The hybrid-
ized slides were washed in 2 X SSC (sodium chloride sodium 
citrate), 0.1% sodium dodecyl sulfate for 2 minutes, 1 X SSC for 
3 minutes, and then 0.2 X SSC for 2 minutes at room temper-
ature. The slides were centrifuged at 3,000 rpm for 20 s to dry. 
The arrays were analyzed using an Axon GenePix 4000B 
scanner with associated software (Molecular Devices Corp., 
Sunnyvale, CA). Gene expression levels were calculated with 
NimbeScan Version 2.4 (Roche NimbleGen, Inc., WI). Rela-
tive signal intensities for each gene were generated using the 
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cessed based on median polish normalization method using 
NimbeScan Version 2.4 (Roche NimbleGen, Inc., WI). This 
normalization method aims to make the distribution of in-
tensities for each array in a set of arrays identical. The normal-
ized, and log transformed intensity values were then analyz-
ed using GeneSpring GX 7.3.1 (Agilent technologies, CA). 
Fold change filters included the requirement that the genes 
be present in at least 150% of controls for up-regulated genes, 
and lower than 66.67% of controls for down-regulated genes. 
Hierarchical clustering data were clustered groups that be-
have similarly across experiments using GeneSpring GX 7.3.1 
(Agilent technologies, CA). Clustering algorithm was Eu-
clidean distance, average linkage.
 
Ribonucleic acid extraction and complementary 
deoxyribonucleic acid synthesis
Total RNA was extracted using trizol reagent
TM (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s protocol, and 
re-suspended in diethyl pyrocarbonate water. The final RNA 
amount was spectrophotometrically determined at 260/280 
nm. Quality was assessed as the absence of smear of 18S and 
28S bands analyze by means of Bio analyzer 2100 (Agilent). 
RNA samples were stored at -70°C until used. cDNAs were 
synthesized by 1 ug of total RNA, according to the manufac-
ture’s protocol (High Capacity RNA-to-cDNA kit, Applied 
Biosystems, USA).
Gene expression analysis by real time reverse 
transcription-polymerase chain reaction
Real-time quantitative polymerase chain reaction (PCR) 
was performed in triplicate in 384-well plates. A 384-well high-
throughput analysis was performed using the ABI Prism 7900 
Sequence Detection System (Applied Biosystems, Calfornia, 
USA), and white colored 384-well plates (ABgene, Hamburg, 
Germany) for intensification of the fluorescent signals by a 
factor of three. The system operates using a thermal cycler and 
a laser that is directed via fiber optics to each well. Fluoresc-
ence emission from each sample was collected by a charge-cou-
pled device-camera, and quantitative data were analyzed us-
ing the Sequence Detection System software (SDS version 2.0, 
Applied Biosystems, California, USA). Reaction mixtures con-
tained 10 pmol/uL of each primer and 2X SYBR Green PCR 
Master Mix (Applied Biosystems, California, USA), which in-
cluded the HotStarTaqt DNA-Polymerase in an optimized 
buffer, the dNTP mix (with dUTP additive), the SYBRs Green 
I fluorescent dye, and ROX dye as a passive reference. Each of 
the 384-well real-time quantitative PCR plate included serial di-
lutions (1, 1/2 and 1/4) of cDNA, which were used to generate 
relative standard curves for genes. 
The resulting first-strand of cDNA was normalized by the 
glyceraldehyde 3-phosphate dehydrogenase gene. The nor-
malized cDNA was used for the PCR procedure as a template. 
The specific primers for rat inducible NO synthase (NOS2) 
was 5’-GGG CCA CCT TTA TGT TTG TG-3’ (forward) and 
5’-CCT CAA CCT GCT CCT CAC TC-3’ (reverse). The spe-
cific primers for rat endothelial NO synthase (eNOS, NOS3) 
were 5’-CTG CGG TGA TGT CAC TAT GG-3’ (forward) and 
5’-AAA TGT CCT CGT GGT AGC GT-3’ (reverse). The spe-
cific primers for rat MMP-2 was 5’-AAG AGG CCT GGT TAC 
CCT GT-3’ (forward) and 5’-AAG TAG CAC CTG GGA 
GGG AT-3’(reverse). The specific primers for rat TIMP were 
5’-GAC CTA TAG TGC TGG CTG TG-3’ (forward) and 5’- 
GATC GCT CTG GTA GCC CTT CT-3’ (reverse) (Table 1). 
All primers were amplified using the same conditions. Ther-
mal cycling conditions 50°C for 2 minutes and 95°C for 10 
minutes, followed by 40 cycles of 95°C for 30 s and 60°C for 
30 s, 72°C for 30 s. In order to exclude the presence of un-
specific products, a melting curve analysis of products was 
performed routinely after finishing amplification by a high-
resolution data collection during an incremental tempera-
ture increase from 60°C to 95°C at a ramp rate of 0.21°C/s. 
We then converted real-time PCR cycle numbers to gene am-
ounts (ng) on the basis of the equation. Real-time PCR anal-
ysis was performed on an Applied Biosystems Prism 7900 Se-
quence Detection System (Applied Biosystems, California, 
USA) (Fig. 1).
Statistical analysis
Results are expressed as the mean±standard deviation. An 
unpaired two-tailed t-test and Mann-Whitney test were used, 
and a p<0.05 was considered statistically significant.
 
Results
Body and organ weight 
The mean body weight decreased significantly in the MCT 
Table 1. Gene sequence of primer of RT-PCR
Gene Forward primer sequence Reverse primer sequence Size
NOS2 GGG CCA CCT TTA TGT TTG TG CCT CAA CCT GCT CCT CAC TC 107 bp
NOS3 CTG CGG TGA TGT CAC TAT GG AAA TGT CCT CGT GGT AGC GT 140 bp
MMP-2 AAG AGG CCT GGT TAC CCT GT AAG TAG CAC CTG GGA GGG AT 137 bp
TIMP1 GAC CTA TAG TGC TGG CTG TG GATC GCT CTG GTA GCC CTT CT 133 bp
NOS2: inducible nitric oxide synthase, NOS3: endothelial nitric oxide synthase, MMP-2: matrix metalloproteinase 2, TIMP: tissue inhibitor of 
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group and the bosentan group, compared to the control group 
on day 1, 5, 7, 14 and 28 (Table 2). 
The RV/(LV+septum) ratio significantly increased in the MCT 
group compared to the control group on day 7 (21.5±2.1% 
vs. 26.1±3.2%), day 14 (22.6±4.8% vs. 33.2±2.7%), day 28 
(19.3±0.8% vs. 46.3±12.1%). The RV/(LV+septum) ratio in-
creased in the bosentan group compared to the control group 
on day 7 (21.5±2.1% vs. 27.9±1.8%), day 14 (22.6±4.8% vs. 
29.2±3.0%). RV/(LV+septum) ratio was also increased in 
the bosentan group on day 28 compared to the control group 
{37.0±6.4% (bosentan) vs. 19.3±0.8% (control)}, but was sig-
nificantly reduced compared to the MCT group {37.0±6.4% 
(bosentan) vs. 46.3±12.1% (MCT)} (Table 2).
The lung to body weight ratio showed significant increase 
after MCT administration when compared to the control gr-
oup on day 14 {0.80±0.08% (MCT) vs. 0.47±0.04% (control)}, 
day 28 {0.79±0.33% (MCT) vs. 0.44±0.01% (control)}. The 
lung to body weight ratio was also increased in the bosentan 
group on day 28 compared to the control group {0.67±0.08% 
(bosentan) vs. 0.44±0.01% (control)}, but was significantly 
reduced compared to the MCT group {0.67±0.08% (bosen-
tan) vs. 0.79±0.33% (MCT)} (Table 2).
Mean right ventricular pressure
The mean RV pressure was significantly increased in MCT 
group compared to the control group on day 14 (22.0±3.7 
mmHg vs. 12.3±3.8 mmHg), day 28 (29.5±3.5 mmHg vs. 
12.0±2.8 mmHg) (p<0.05) (Table 3). After bosentan treatment, 
mean RV pressures significantly decreased from 22.0±3.7 
mmHg to 16.3±2.5 mmHg on day 14 and from 29.5±3.5 
mmHg to 15.0±3.0 mmHg on day 28 (Table 3). 
Nitric oxide level in serum 
Serum NO concentration increased in the MCT and in the 
bosentan groups on day 1 and 14 but the difference was not 
statistically significant. There were no significance in the ch-
anges of serum NO level on day 28 between the MCT and 
bosentan groups (Table 4).
Matrix metalloproteinase-2 level in serum
Serum MMP-2 level was significantly increased in the MCT 
group compared to the control group on day 28 {254.21±36.27 
ng/mL (MCT) vs. 198.37±10.57 ng/mL (control)} (Table 5). 
But there were no significant changes in MMP-2 level after bos-
entan treatment.
501 bp
489 bp
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331 bp
242 bp
190 bp
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67 bp
Rat
GAPDH
89
NOS2
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Fig. 1. Typical example of RT-PCR products are shown for the lev-
el of inducible nitric oxide synthase endothelial nitric oxide synth-
ase, matrix metalloproteinase 2 and tissue inhibitor of matrix metal-
loproteinases messenger ribonucleic acid in lung tissue. The RT-
PCR products from the transcripts of NOS2, NOS3, MMP2, TIMP 
and GAPDH were 107 bp, 140 bp, 137 bp, 133 bp and 89 bp. NOS 
2: inducible nitric oxide synthase, NOS3: endothelial nitric oxide syn-
thase, MMP2: matrix metalloproteinase 2,TIMP1: tissue inhibitor of 
matrix metalloproteinases, RT-PCR: reverse transcription-polymer-
ase chain reaction. 
Table 2. Changes in body weight, RV weight, LV and septum weight and RV/LV+septum, lung/body weight
 Days  group N Body weight (g)  RV (g) LV+septum (g)  RV/(LV+S) (%) Lung/Body weight (%)
1 0  Control 6 192.0±2.5 0.11±0.02 0.52±0.04 21.4±3.1 0.56±0.02
01   MCT 6 193.7±2.5 0.12±0.01 0.52±0.05 22.9±3.6 0.54±0.02
01   Bosentan 6 193.0±5.3 0.12±0.02 0.54±0.03 22.5±3.3 0.60±0.08
50   Control 6 234.2±7.4 0.16±0.02 0.64±0.05 24.4±3.4 0.52±0.02
01   MCT 6 197.6±5.3† 0.14±0.01 0.53±0.04† 26.3±1.9 0.40±0.31
01   Bosentan 6 200.1±9.4† 0.14±0.02 0.52±0.04† 27.1±2.1 0.56±0.05
70   Control 6 254.2±5.3 0.14±0.01 0.66±0.02 21.5±2.1 0.48±0.02
01   MCT 6 228.1±14.5† 0.14±0.02 0.55±0.04† 26.1±3.2† 0.61±0.07
01   Bosentan 6 213.2±6.2†‡ 0.15±0.01 0.53±0.02† 27.9±1.8† 0.59±0.04
14   Control 6 291.2±21.7 0.16±0.04 0.72±0.10 22.6±4.8 0.47±0.04
01   MCT 6 266.9±9.8* 0.22±0.02† 0.66±0.02 33.2±2.7† 0.80±0.08†
01   Bosentan 6 261.2±11.7* 0.23±0.02† 0.68±0.04 29.2±3.0† 0.72±0.07†
28   Control 3 362.3±15.6 0.18±0.01 0.92±0.03 19.3±0.8 0.44±0.01
01   MCT 6 291.7±30.6* 0.34±0.08* 0.74±0.04* 46.3±12.1* 0.79±0.33†
01   Bosentan 3 289.7±50.7 0.30±0.06†‡ 0.68±0.12* 37.0±6.4†‡ 0.67±0.08†‡
*vs. control group p<0.05, †vs. control group p<0.01, ‡vs. MCT group p<0.05. MCT: monocrotaline, LV: left ventricle, RV: right ventricle, S: 
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Microarray of the lung tissue
Genes which expression was more than twice beyond the 
control group were selected. NOS2, NOS3, MMP-2 and TI-
MP genes in MCT group were more than twice beyond the 
control group.
Expression of nitric oxide synthase 2 messenger 
ribonucleic acid in rat lung tissue
The expression of NOS2 messenger ribonucleic acid (mRNA) 
was not different between the two groups. Bosentan did not 
modify the pulmonary expression of the NOS2 gene (Fig. 2). 
Expression of nitric oxide synthase 3 messenger 
ribonucleic acid in rat lung tissue
The expression of NOS3 mRNA was significantly increas-
ed in the MCT group, compared to the control group on day 
28 (3.51±1.18 vs. 1±0.37). 
The expression levels of NOS3 genes were significantly de-
creased after bosentan treatment on day 28 (2.16±1.37) (Fig. 3).
Expression of matrix metalloproteinas-2 messenger 
ribonucleic acid in rat lung tissue
MMP-2 gene expressions were significantly increased in 
MCT-treated rats compared to the control group on day 5 
(2.29±0.77 vs. 1±0.09) and day 28 (3.5±1.18 vs. 1±0.37). 
The gene expressions of MMP-2 were significantly decr-
eased after bosentan treatment on day 7 (1.14±0.31 vs. 0.52± 
0.17) and day 28 (3.51±1.18 vs. 1.55±1.14) (Fig. 4). 
Expression of tissue inhibitor of matrix 
metalloproteinases-1 messenger ribonucleic acid 
in rat lung tissue
The gene expression of TIMP-1 was significantly increased 
in MCT-treated rats compared to the control group on day 
28 (7.09±2.28 vs. 1±0.67). 
The gene expression of TIMP-1 was significantly decreased 
after bosentan treatment on day 28 (3.83±2.74) (Fig. 5). 
Discussion
ECs are recognized as major regulators of vascular func-
tion, and endothelial dysfunction implies a multifaceted im-
balance in EC production of vasoconstrictors versus vasodi-
lators, activators versus inhibitors of SMC growth and migr-
ation, prothrombotic versus antithrombotic mediators, and 
pro-inflammatory versus anti-inflammatory signals.
7)
We confirmed MCT-induced pulmonary hypertension by 
pathologic findings and ET-1 gene expression changes in our 
previous report.
8) The predominant changes in pulmonary 
vasculature included increased number of intra-acinar mus-
Table 3. Right ventricular pressure in each group (mmHg)
Days Control group MCT group Bosentan group
01 13.2±3.1 14.6±1.7* 10.3±1.1†
05 07.8±1.3 19.0±7.1* 12.7±2.3†
07 09.5±1.7 14.3±4.3* 10.7±1.8†
14 12.3±3.8  22.0±3.7*  16.3±2.5†
28 12.0±2.8  29.5±3.5*  15.0±3.0†
*vs. control group p<0.05, †vs. MCT group p<0.05. MCT: mono-
crotaline 
Table 4. Changes in serum nitric oxide level in each group (μmol/L)
Days Control group MCT group Bosentan group
01 4.25±0.96 8.50±4.65 9.67±2.31
05 4.34±1.21 6.83±0.85 7.12±0.76
07 5.50±2.35 7.67±4.50 07.0±3.22
14 4.50±1.87 6.25±3.86 04.0±3.29
28 04.0±2.64 04.0±1.73 05.0±5.66
p>0.05. MCT: monocrotaline
Table 5. Changes in serum MMP-2 level in each group (ng/mL)
Days  Control group MCT group Bosentan group
01 263.81±34.00 292.27±11.86 310.19±26.24 
05 250.81±15.00 260.27±7.67 260.28±28.32
07 247.41±11.97 257.59±45.93 279.59±41.43
14 198.37±10.57 254.21±36.27 252.22±55.09
28 181.08±13.77 256.61±62.47* 184.20±25.45
*vs. control group p<0.05. MMP: matrix metalloproteinase, MCT: mo-
nocrotaline
Control
Monocrotaline
Bosentan
Fig. 2. Gene expression of inducible nitric oxide synthase after bo-
sentan treatment. 
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Fig. 3. Gene expression of endothelial nitric oxide synthase after bo-
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cular arteries from 1 day after MCT administration, and the 
development of medial thickening in the pulmonary arteri-
oles in the MCT group from 1 week. A progressive increase in 
the ratio of RV to LV and septum was noted from 2 weeks in 
our previous study
8) and the present study. These pathologic 
findings were accompanied by significant rise in pulmonary 
blood pressure and apparent RVH after MCT injection.
4)9)10) 
In the present study and previous study,
11) ET-1 and MMP 
gene increased as early as 5 days in the course of MCT treat-
ment, suggesting their contribution to progression of cardio-
pulmonary pathology in rats with MCT-induced pulmonary 
hypertension. Up-regulation of eNOS gene was noted signifi-
cantly on day 28, suggesting that it is involved in the com-
pensation mechanism. 
Administration of bosentan reduced lung vascular hyper-
trophy and RVH. The gene expression of MMP significantly de-
creased on day 7 and day 28 after bosentan treatment. eNOS 
and TIMP genes significantly decreased on day 28 after bo-
sentan treatment. NO is a potent endogenous vasodilator sy-
nthesized by the action of eNOS in lung and other tissues. It 
is well known that impaired production of NO can be one of 
the causes leading to pulmonary hypertension,
12) but the role 
eNOS expression plays on pulmonary hypertension is yet to 
be determined. 
Reduced expression of eNOS was observed in the lungs of 
patients with pulmonary hypertension compared to lungs of 
normal healthy subjects.
13) On the other hand, others have de-
monstrated up-regulation of eNOS protein expression in pul-
monary hypertensive subjects.
1)14) 
Pulmonary hypertension is induced by MCT experimen-
tally in rats.
15) MCT is a pyrrolizine alkaloid which selectively 
injures the vascular endothelium of the lung and induces pul-
monary vasculitis.
16) Muscularization and hypertrophy of 
pulmonary artery media lead to increased vascular resistance 
and pulmonary arterial pressure.
17) MCT-induced pulmo-
nary hypertension is associated with the development of RVH 
within weeks, depending on the dose of MCT and the age of 
the rats.
17) In our study, rats were treated with sc injection of 
60 mg/kg MCT to induce RVH. 
In our study, eNOS mRNA significantly increased in MCT-
induced pulmonary hypertension rats on day 28, consistent 
with other studies.
18)19) Tyler et al.
18) reported increased levels 
of eNOS mRNA in MCT-treated rats although eNOS protein 
levels decreased. Up-regulation of arterial eNOS in lungs of 
MCT treated rats was also demonstrated by Resta et al.
19) al-
though some showed that MCT did not alter the expression 
of eNOS mRNA in rat lungs.
20) 
The regulation of eNOS expression in other forms of pul-
monary hypertension has been investigated in various animal 
models. eNOS mRNA expression and eNOS protein incre-
ased in the lungs of rats with increased pulmonary flow,
21) 
which developed pulmonary artery medial hypertrophy pri-
or to development of pulmonary hypertension.
22) Similar re-
sults were shown by Black et al.
23) who demonstrated early up-
regulation of eNOS gene expression and activity in lambs 
with increased pulmonary blood flow and pulmonary hyper-
tension. They suggested increased pulmonary blood flow re-
sulted in increased shear stress which up-regulated eNOS ex-
pression, which in turn increased the production of NO to mi-
nimize vascular resistance in the early stages of pulmonary hy-
pertension. However, other models of pulmonary hypertension 
have also shown up-regulation of eNOS independent of shear 
stress. eNOS expression was also up-regulated in hypoxia-in-
duced pulmonary hypertension models.
24) Le Cras et al.
25) sug-
gested that pulmonary blood oxygenation may play a factor 
in the up-regulation of eNOS in chronic hypoxia. Possible me-
chanisms proposed for the up-regulation of eNOS after ch-
ronic hypoxia are as follows: a result of polycythemia, hyper-
trophy and hyperplasia of ECs associated with pulmonary 
vascular remodeling, increased rates of transcription or in-
creased eNOS mRNA stability.
26) The hypothesis that hypoxia, 
rather than hemodynamic factors, contributes to the up-regu-
lation of eNOS was supported by the study performed by Le 
Cras et al.
25) where eNOS expression remained up-regulated 
in a setting of decreased blood flow due to left lung pulmo-
nary artery stenosis. However, in a study of posthypoxic rats 
in recovery state from chronic hypoxia, eNOS expression ma-
intained up-regulated. This suggests hypoxia may be the ini-
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Fig. 5. Gene expression of tissue inhibitor of matrix metalloproteinases 
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tiating factor for up-regulation of eNOS, but not the only fac-
tor that controls eNOS expression. From the increased ex-
pression of eNOS in MCT-induced pulmonary hypertension 
shown in our study and by the others,
18)19) we suggest that 
regulation of eNOS expression is controlled by other factors 
than hypoxia. However, possible factors leading to the up-
regulation of eNOS expression in MCT-induced pulmonary 
hypertension remains unclear. 
Despite increased levels of eNOS mRNA after 28 days of 
MCT treatment, there was no significant change in serum NO 
level in the current study. As in our study, increased eNOS 
expression did not lead to increased NO production in other 
studies of pulmonary hypertension.
27) Several mechanisms 
have been proposed for the discordance between NO produc-
tion and increased eNOS expression in vitro and in vivo.
28) 
They include impaired arginine uptake, decreased heat 
shock protein-90 levels, and decreased O2 tension. In addi-
tion, a limitation of this study is that it remain unclear wheth-
er the discordance between eNOS expression and serum NO 
level was due to reduced translation, or a blunted response at 
the post-translational level because eNOS protein expression 
or activity was not measured.
In a recent report by Mukhopadhyay et al.
29) the intracellu-
lar vesicular trafficking theory was proposed as the mecha-
nism of eNOS up-regulation in MCT-induced pulmonary 
hypertension. They demonstrated that MCT produced a 
Golgi blockade in pulmonary artery ECs, leading to seques-
tration of eNOS away from its functional caveolar location. 
This provided a novel insight in the mechanisms of the often 
reported reduction in pulmonary NO levels in experimental 
pulmonary hypertension, despite sustained eNOS protein 
levels. 
In our study, the mean body weight was significantly de-
creased in MCT treated rats compared to the control group, 
which was a sign of heart failure comparable to cachexia in 
patients with chronic heart failure. The lung to body weight 
ratio increased in the MCT group compared to the control 
group, which indicated the presence of an extensive prolifer-
ative pulmonary response in the MCT treated rats. These fi-
ndings were consistent with that shown by Marleen et al.
16) 
The RV/(LV+septum) ratio, which can be thought of, as an 
index of RVH significantly increased in the MCT group from 
day 14. Thus, MCT treatment resulted in RVH and pulmo-
nary arterial hypertension in our study as expected. 
Bosentan is efficacious in experimental and clinical pulmo-
nary hypertension.
4) It is well-known that bosentan improves 
hemodynamics, increases exercise capacity, and decreases 
the rate of clinical worsening in patients with World Health 
Organization Class III or IV pulmonary arterial hypertension. 
One of the important findings in our study was that bosen-
tan treatment decreased the RV/(LV+septum) ratio of MCT 
treated rats on day 28. This means that bosentan treatment 
attenuated RVH in MCT-induced pulmonary hypertension 
model. These findings are consistent with previous data re-
ported by other researchers, in which improved survival
4) 
and decreased RVH were demonstrated in MCT-treated rats 
after bosentan administration.
3)4) In other studies, bosentan 
was shown to improve endothelium-dependent relaxation in 
various animals
4)30) and furthermore, to increase exercise ca-
pacity and improve hemodynamics in patients with pulmo-
nary hypertension.
3) 
In this study, the gene expression of MMP-2 significantly de-
creased after bosentan treatment on day 7 and 28. The expres-
sion levels of NOS3 and TIMP-1 genes significantly decreased 
after bosentan treatment on day 28. 
The inhibitory effects of bosentan on pulmonary hyper-
tension influenced the gene expressions of NOS3, MMP and 
TIMP. Typical pulmonary artery lesions in idiopathic pul-
monary hypertension include adventitial thickening, medial 
hypertrophy, SMC proliferation and ECM accumulation.
6) 
MMPs are matrix-degrading enzymes involved in ECM 
turnover, and in SMC and EC migration and proliferation.
6) 
It has been shown that over-activity of MMPs in the lung is 
likely to contribute to pulmonary disease progression.
31) There 
is also evidence to suggest that MMP expression is up-regu-
lated in pulmonary arterial hypertension.
19) Increased levels 
of MMP-2 were also reported in the plasma of patients with 
heart failure, ischemic and idiopathic DCM, implicating that 
activation of MMPs may play an important role in ventricu-
lar remodeling.
17) In the present study, serum MMP-2 level 
was significantly increased in the MCT-treated rats that de-
veloped RVH after 28 days of MCT injection. This finding is 
consistent with a previous report by Umar et al.
17) who sh-
owed activation of immunoreactive MMP-2 and MMP-9 in 
the remodeled RV myocardium of rats with pulmonary hy-
pertension induced RV failure. Thus, our results support pre-
vious findings by other researchers
5)6) that MMPs contribute 
to pulmonary arterial hypertension progression in animals. 
NO and reactive oxygen species produce peroxynitrite, 
known to activate MMPs.
17) Umar et al.
17) demonstrated the 
stimulating effect of NO on the expression of MMP-2, and sug-
gested that neuronal NOS activation may be responsible for 
increased immunoreactivity of MMP-2. We proposed that 
eNOS expression be responsible for the activation of MMPs, as 
increased eNOS expression after 28 days of MCT treatment 
coincided with the timing of significant elevation of serum 
MMP level in our study. Further investigation is necessary to 
assess this hypothesis and elucidate the underlying mecha-
nisms.
In conclusion, MCT treated rats developed RV hypertro-
phy and pulmonary arterial hypertension. The eNOS , MMP-
2 and TIMP-1 genes were up-regulated in MCT-treated rats, 
which suggests cardiac hypertrophy increases synthesis of 
ECM component. Treatment with bosentan attenuated RVH 90   Nitric Oxide Synthase and MMP-2 in Pulmonary Hypertension 
and the gene expressions of MMP-2, TIMP-1 and eNOS in 
the MCT treated rats. More invasive studies are needed to 
investigate the changes of eNOS and MMP gene expressions 
in a chronic MCT-induced pulmonary hypertension model.
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